We are pleased to announce the launch of a new independent educational resource created by Springer Healthcare IME for the rare disease, Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID).
New Horizons in the Management of ADA-SCID www.ada-scid.online is an independent initiative steered by an editorial board of multidisciplinary experts: Andrew Gennery, Bobby Gaspar and Robbert Bredius. It is designed to educate healthcare professionals who are presented with ADA-SCID patients, in the biology of the disease, how to screen for it, and current and emerging treatments.
New Horizons in the Management of ADA-SCID aims to facilitate this understanding by providing direct access to the latest research and commentary in the form of:
New Horizons in the Management of ADA-SCID is produced by Springer Healthcare IME. This educational activity is supported by an educational grant from GlaxoSmithKline.
Bios and Disclosures:
Dr Andrew Gennery, Watson Reader/Honorary Consultant in Paediatric Immunology & Haematopoeitic Stem Cell Transplantation. Newcastle University and Great North Children’s Hospital, Newcastle upon Tyne, UK.
Dr Gennery has delivered lectures as part of an ‘in- house’ education staff to GSK Staff – Haematopoietic Stem Cell Transplantation for Primary Immunodeficiencies.
Professor Bobby Gaspar, Professor of Paediatrics and Immunology; Consultant in Paediatric Immunology; Head, Rare Diseases Theme; Head, Molecular and Cellular Immunology Section. UCL Great Ormond Street Institute of Child Health, UK.
Professor Gaspar is founder and Chief Scientific Officer for Orchard Therapeutics, a new company that is developing a lentiviral gene therapy approach for ADA-SCID.
Dr Robbert Bredius, MD PhD, Paediatric Immunologist – Infectious Disease – Stem Cell Transplant Dr. Department of Paediatrics, Immunology section, Hematology and Stem Cell Transplantation, Leiden University Medical Centre, The Netherlands.
Dr Bredius has delivered industry symposia presentations funded by GSK.